Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352683 | 0.93 | ZDHHC2 (0.52) | ZDHHC2L3MBTL1 | |
| SCHEMBL18355438 | 0.92 | MAPT (0.51) | ZDHHC2MAPTALDH1A1LMNATHRB | |
| SCHEMBL18355254 | 0.91 | ZDHHC2 (0.51) | ZDHHC2RECQLL3MBTL1 | |
| SCHEMBL18354884 | 0.86 | ZDHHC2 (0.47) | ZDHHC2ALDH1A1LMNARECQLL3MBTL1 | |
| SCHEMBL18352553 | 0.85 | ZDHHC2 (0.48) | ZDHHC2LMNA | |
| SCHEMBL18354876 | 0.84 | HTT (0.58) | MAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL18354871 | 0.83 | TAAR1 (0.50) | ZDHHC2 | |
| SCHEMBL18406535 | 0.82 | NAAA (0.55) | MAPTALDH1A1LMNA | |
| SCHEMBL1892954 | 0.81 | SMN1; SMN2 (0.64) | RECQLL3MBTL1 | |
| SCHEMBL18354903 | 0.80 | ATM (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | ZDHHC2 153/4885MAPT 8/4885ALDH1A1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.